CLSA Statement on Outcome of AB 463

SACRAMENTO – April 29, 2015 – Eve Bukowski, vice president of state government affairs for the California Life Sciences Association (CLSA), a non-profit representing more than 750 leading life sciences organizations, issued the following statement regarding the outcome of Assembly Bill (AB) 463 in the California State Assembly Committee on Health:

“Yesterday was a good day for patients, as AB 463 was not brought up for a vote in the California State Assembly Committee on Health.

“We remain opposed to AB 463, as it would have done nothing to ensure patient access to necessary treatments, exclusively targeted a sector providing life saving medicines, and failed to recognize the clinical and economic value to patients and the healthcare system provided by these life saving medications.

“Continued development of new medicines is an essential part of the solution to improving healthcare for all, transforming patient care, averting premature death, and returning a net economic benefit to society.”

About California Life Sciences Association (CLSA)California Life Sciences Association (CLSA) is the leading voice for California’s life sciences sector. We work closely with industry, government, academia and other stakeholders to shape public policy, drive business solutions and grow California’s life sciences innovation ecosystem. CLSA serves over 750 biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors and service providers. CLSA was founded in 2015 when the Bay Area Bioscience Association (BayBio) and the California Healthcare Institute (CHI) merged to create the state’s most influential life sciences advocacy and business leadership organization. Visit CLSA at www.califesciences.org, and follow us on Twitter @CALifeSciences, Facebook, Instagram, LinkedIn and YouTube.